My suggestion is to take some profits along the way. If the company has success with the clinical trial, and is not just some phony baloney PR success, then we could see this rise a bit. Upon CE mark approval it could rise a bit more. I think it is possible that the pps could get back to .40 or so where a lot of the current bagholders bought in. I would get out at that point because when the sales numbers come in, this will disappoint. I see some trading opportunities in all of this, but then the stock settles back and stagnates for a long while.
Market Data 
Markets 
AI
